While numerous studies have assessed the viability of elevated plasma GFAP as a biomarker for AD and amyloid pathology [1, 3, 11, 14, 17, 37, 43, 49], few have focused on changes in GFAP expression in brain. Here, GFAP is linked to amyloidosis.